|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q53141782
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010841.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q53141782
|
|
024
|
|
|
‡a
0000-0003-0432-3133
‡2
orcid
|
|
024
|
|
|
‡a
7005192001
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q53141782
|
|
100
|
0 |
|
‡a
Fernando Pastor
‡9
ast
‡9
es
‡9
sl
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Fernando Pastor
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Fernando Pastor
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
|
|
670
|
|
|
‡a
Author's A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
|
|
670
|
|
|
‡a
Author's Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
|
|
670
|
|
|
‡a
Author's An RNA toolbox for cancer immunotherapy
|
|
670
|
|
|
‡a
Author's Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression.
|
|
670
|
|
|
‡a
Author's Aptamer-iRNAs as Therapeutics for Cancer Treatment
|
|
670
|
|
|
‡a
Author's Aptamers: A Feasible Technology in Cancer Immunotherapy
|
|
670
|
|
|
‡a
Author's Aptamers: A New Technological Platform in Cancer Immunotherapy
|
|
670
|
|
|
‡a
Author's BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
|
|
670
|
|
|
‡a
Author's Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
|
|
670
|
|
|
‡a
Author's Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.
|
|
670
|
|
|
‡a
Author's Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.
|
|
670
|
|
|
‡a
Author's Dendritic cell vaccination in glioblastoma after fluorescence-guided resection
|
|
670
|
|
|
‡a
Author's Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation
|
|
670
|
|
|
‡a
Author's Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).
|
|
670
|
|
|
‡a
Author's Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
|
|
670
|
|
|
‡a
Author's Idiotype vaccine production using hybridoma technology
|
|
670
|
|
|
‡a
Author's Idiotype vaccines for human B-cell malignancies
|
|
670
|
|
|
‡a
Author's Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses
|
|
670
|
|
|
‡a
Author's Idiotype vaccines for lymphoma therapy.
|
|
670
|
|
|
‡a
Author's In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding.
|
|
670
|
|
|
‡a
Author's Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
|
|
670
|
|
|
‡a
Author's Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
|
|
670
|
|
|
‡a
Author's Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14
|
|
670
|
|
|
‡a
Author's MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells
|
|
670
|
|
|
‡a
Author's Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.
|
|
670
|
|
|
‡a
Author's Prolonged idiotypic vaccination against follicular lymphoma.
|
|
670
|
|
|
‡a
Author's SC-01HnRNPA1 PROTEIN DEREGULATES Baf45d mRNA SPLICING IN GLIOMA: FUNCTION AND MECHANISM.
|
|
670
|
|
|
‡a
Author's Stem cell transplant and idiotypic vaccination for B-cell malignancies.
|
|
670
|
|
|
‡a
Author's Successful idiotypic vaccination following stem cell allotransplant in lymphoma
|
|
670
|
|
|
‡a
Author's Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
|
|
670
|
|
|
‡a
Author's Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.
|
|
670
|
|
|
‡a
Author's The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
|
|
670
|
|
|
‡a
Author's Tumor-targeted costimulation by using bi-specific aptamers
|
|
670
|
|
|
‡a
Author's U1A is a positive regulator of the expression of heterologous and cellular genes involved in cell proliferation and migration
|
|
909
|
|
|
‡a
(orcid) 0000000304323133
‡9
1
|
|
909
|
|
|
‡a
(scopus) 7005192001
‡9
1
|
|
919
|
|
|
‡a
aptamerirnasastherapeuticsforcancertreatment
‡A
Aptamer-iRNAs as Therapeutics for Cancer Treatment
‡9
1
|
|
919
|
|
|
‡a
aptamersafeasibletechnologyincancerimmunotherapy
‡A
Aptamers: A Feasible Technology in Cancer Immunotherapy
‡9
1
|
|
919
|
|
|
‡a
dendriticcellvaccinationinglioblastomaafterfluorescenceguidedresection
‡A
Dendritic cell vaccination in glioblastoma after fluorescence-guided resection
‡9
1
|
|
919
|
|
|
‡a
aptamersanewtechnologicalplatformincancerimmunotherapy
‡A
Aptamers: A New Technological Platform in Cancer Immunotherapy
‡9
1
|
|
919
|
|
|
‡a
identificationoflag3highaffinityaptamersbyhtselexandconservedmotifaccumulation
‡A
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation
‡9
1
|
|
919
|
|
|
‡a
biovaxidacustomizedidiotypevaccineforthetreatmentofbcelllymphoma
‡A
BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
‡9
1
|
|
919
|
|
|
‡a
identificationoflag3highaffinityaptamersbyhtselexandconservedmotifaccumulationcma
‡A
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).
‡9
1
|
|
919
|
|
|
‡a
clinicalbenefitassociatedwithidiotypicvaccinationinpatientswithfollicularlymphoma
‡A
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma
‡9
1
|
|
919
|
|
|
‡a
identificationoftim32fluorooligonucleotideaptamerbyhtselexforcancerimmunotherapy
‡A
Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
‡9
1
|
|
919
|
|
|
‡a
clinicalsafetyandimmunogenicityoftumortargetedplantmadeidklhconjugatevaccinesforfollicularlymphoma
‡A
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.
‡9
1
|
|
919
|
|
|
‡a
idiotypevaccineproductionusinghybridomatechnology
‡A
Idiotype vaccine production using hybridoma technology
‡9
1
|
|
919
|
|
|
‡a
decoybasedtargetedinhibitionofstat3anewstepforwardforbcelllymphomaimmunotherapy
‡A
Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.
‡9
1
|
|
919
|
|
|
‡a
mrp1cd28bispecificoligonucleotideaptamerstargetcostimulationtodrugresistantmelanomacancerstemcells
‡A
MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells
‡9
1
|
|
919
|
|
|
‡a
lipopolysaccharideneedssolublecd14tointeractwithtlr4inhumanmonocytesdepletedofmembranecd14
‡A
Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14
‡9
1
|
|
919
|
|
|
‡a
intratumoralinjectionofactivatedblymphoblastincombinationwithpd1blockadeinducessystemicantitumorimmunitywithreductionoflocalanddistaltumors
‡A
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
‡9
1
|
|
919
|
|
|
‡a
inductionoftumourimmunitybytargetedinhibitionofnonsensemediatedmrnadecay
‡A
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
‡9
1
|
|
919
|
|
|
‡a
insilicoaptamerdockingstudiesfromaretrospectivevalidationtoaprospectivecasestudytim3aptamersbinding
‡A
In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study-TIM3 Aptamers Binding.
‡9
1
|
|
919
|
|
|
‡a
idiotypevaccinesforlymphomatherapy
‡A
Idiotype vaccines for lymphoma therapy.
‡9
1
|
|
919
|
|
|
‡a
idiotypevaccinesforlymphomapotentialfactorspredictingtheinductionofimmuneresponses
‡A
Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses
‡9
1
|
|
919
|
|
|
‡a
u1aisapositiveregulatoroftheexpressionofheterologousandcellulargenesinvolvedincellproliferationandmigration
‡A
U1A is a positive regulator of the expression of heterologous and cellular genes involved in cell proliferation and migration
‡9
1
|
|
919
|
|
|
‡a
tumortargetedcostimulationbyusingbispecificaptamers
‡A
Tumor-targeted costimulation by using bi-specific aptamers
‡9
1
|
|
919
|
|
|
‡a
aberrantsplicingofbaf45dlinkssplicingregulationandtranscriptioninglioblastoma
‡A
The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.
‡9
1
|
|
919
|
|
|
‡a
targetinginhibitionoffoxp3byacd282flurooligonucleotideaptamerconjugatedtop60peptideenhancesactivecancerimmunotherapy
‡A
Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.
‡9
1
|
|
919
|
|
|
‡a
targeting41bbcostimulationtodisseminatedtumorlesionswithbispecificoligonucleotideaptamers
‡A
Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.
‡9
1
|
|
919
|
|
|
‡a
successfulidiotypicvaccinationfollowingstemcellallotransplantinlymphoma
‡A
Successful idiotypic vaccination following stem cell allotransplant in lymphoma
‡9
1
|
|
919
|
|
|
‡a
stemcelltransplantandidiotypicvaccinationforbcellmalignancies
‡A
Stem cell transplant and idiotypic vaccination for B-cell malignancies.
‡9
1
|
|
919
|
|
|
‡a
sc01hnrnpa1proteinderegulatesbaf45dmrnasplicingingliomafunctionandmechanism
‡A
SC-01HnRNPA1 PROTEIN DEREGULATES Baf45d mRNA SPLICING IN GLIOMA: FUNCTION AND MECHANISM.
‡9
1
|
|
919
|
|
|
‡a
prolongedidiotypicvaccinationagainstfollicularlymphoma
‡A
Prolonged idiotypic vaccination against follicular lymphoma.
‡9
1
|
|
919
|
|
|
‡a
idiotypevaccinesforhumanbcellmalignancies
‡A
Idiotype vaccines for human B-cell malignancies
‡9
1
|
|
919
|
|
|
‡a
multivalent41bbbindingaptamerscostimulatecd8+tcellsandinhibittumorgrowthinmice
‡A
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.
‡9
1
|
|
919
|
|
|
‡a
2fluorornaoligonucleotidecd40targetedaptamersforthecontrolofblymphomaandbonemarrowaplasia
‡A
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
‡9
1
|
|
919
|
|
|
‡a
phase2trialofautologousdendriticcellvaccinationandradiochemotherapyfollowingfluorescenceguidedsurgeryinnewlydiagnosedglioblastomapatients
‡A
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
‡9
1
|
|
919
|
|
|
‡a
agonistsofcostimulationincancerimmunotherapydirectedagainstcd137ox40gitrcd27cd28andicos
‡A
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
‡9
1
|
|
919
|
|
|
‡a
rnatoolboxforcancerimmunotherapy
‡A
An RNA toolbox for cancer immunotherapy
‡9
1
|
|
919
|
|
|
‡a
antiinflammatorycytokinesinducelipopolysaccharidetoleranceinhumanmonocyteswithoutmodifyingtolllikereceptor4membraneexpression
‡A
Anti-inflammatory cytokines induce lipopolysaccharide tolerance in human monocytes without modifying toll-like receptor 4 membrane expression.
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
SUDOC|281744351
|
|
996
|
|
|
‡2
BAV|495_288793
|
|
996
|
|
|
‡2
ISNI|0000000059446673
|
|
996
|
|
|
‡2
SUDOC|077273923
|
|
996
|
|
|
‡2
BNE|XX1725188
|
|
996
|
|
|
‡2
DNB|1056402288
|
|
996
|
|
|
‡2
BNF|12451328
|
|
996
|
|
|
‡2
NYNYRILM|269936
|
|
996
|
|
|
‡2
DNB|1060696479
|
|
996
|
|
|
‡2
BNCHL|10000000000000000218485
|
|
996
|
|
|
‡2
LC|n 83145132
|
|
996
|
|
|
‡2
ISNI|0000000059202601
|
|
996
|
|
|
‡2
SUDOC|033669252
|
|
996
|
|
|
‡2
ISNI|000000006891183X
|
|
996
|
|
|
‡2
RERO|A017964144
|
|
996
|
|
|
‡2
BLBNB|000344576
|
|
996
|
|
|
‡2
BNC|981058517700606706
|
|
996
|
|
|
‡2
BNE|XX1596243
|
|
996
|
|
|
‡2
SUDOC|259262412
|
|
996
|
|
|
‡2
ISNI|0000000026254093
|
|
996
|
|
|
‡2
BNE|XX1179087
|
|
996
|
|
|
‡2
BNE|XX1014671
|
|
996
|
|
|
‡2
LC|n 93099565
|
|
996
|
|
|
‡2
ISNI|0000000498206460
|
|
996
|
|
|
‡2
BNE|XX959035
|
|
996
|
|
|
‡2
BNC|981058509231606706
|
|
996
|
|
|
‡2
BNC|981058528412706706
|
|
996
|
|
|
‡2
RERO|A027205203
|
|
996
|
|
|
‡2
PTBNP|249150
|
|
996
|
|
|
‡2
LIH|LNB:BFVO;=BJ
|
|
996
|
|
|
‡2
DNB|1061386449
|
|
996
|
|
|
‡2
SUDOC|190932961
|
|
996
|
|
|
‡2
NTA|395394732
|
|
996
|
|
|
‡2
LC|n 82056630
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
